Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial.

Autor: Ulander L; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Tolppanen H; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Hartman O; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Rissanen TT; Heart Center, North Karelia Central Hospital, Siunsote, Joensuu, Finland., Paakkanen R; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Kuusisto J; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Anttonen O; Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland., Nieminen T; Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland., Yrjölä J; Department of Internal Medicine, Kymenlaakson Central Hospital, Kotka, Finland., Ryysy R; Department of Internal Medicine, Kymenlaakson Central Hospital, Kotka, Finland., Drews T; Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland., Utriainen S; Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland., Karjalainen P; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Anttila I; Department of Internal Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland., Nurmi K; Department of Rheumatology, Helsinki University Hospital, Helsinki University, ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland., Silventoinen K; Department of Rheumatology, Helsinki University Hospital, Helsinki University, ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland., Koskinen M; Helsinki Biobank, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Kovanen PT; Wihuri Research Institute, Biomedicum, Helsinki, Finland., Lehtonen J; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland., Eklund KK; Department of Rheumatology, Helsinki University Hospital, Helsinki University, ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland., Sinisalo J; Heart and Lung Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland. Electronic address: juha.sinisalo@hus.fi.
Jazyk: angličtina
Zdroj: International journal of cardiology [Int J Cardiol] 2021 Aug 15; Vol. 337, pp. 21-27. Date of Electronic Publication: 2021 May 04.
DOI: 10.1016/j.ijcard.2021.04.062
Abstrakt: Objectives: To determine the anti-inflammatory effect and safety of hydroxychloroquine after acute myocardial infarction.
Method: In this multicenter, double-blind, placebo-controlled OXI trial, 125 myocardial infarction patients were randomized at a median of 43 h after hospitalization to receive hydroxychloroquine 300 mg (n = 64) or placebo (n = 61) once daily for 6 months and, followed for an average of 32 months. Laboratory values were measured at baseline, 1, 6, and 12 months.
Results: The levels of interleukin-6 (IL-6) were comparable at baseline between study groups (p = 0.18). At six months, the IL-6 levels were lower in the hydroxychloroquine group (p = 0.042, between groups), and in the on-treatment analysis, the difference at this time point was even more pronounced (p = 0.019, respectively). The high-sensitivity C-reactive protein levels did not differ significantly between study groups at any time points. Eleven patients in the hydroxychloroquine group and four in the placebo group had adverse events leading to interruption or withdrawal of study medication, none of which was serious (p = 0.10, between groups).
Conclusions: In patients with myocardial infarction, hydroxychloroquine reduced IL-6 levels significantly more than did placebo without causing any clinically significant adverse events. A larger randomized clinical trial is warranted to prove the potential ability of hydroxychloroquine to reduce cardiovascular endpoints after myocardial infarction.
Competing Interests: Declaration of Competing Interest JS reports personal fees from Abbott, Amgen, and Bayer and a grant from AstraZeneca. PTK reports personal fees from Amgen, Novartis, Raisio Group, and Sanofi.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: